目的：替扎尼定是具有解痙作用的α２腎上腺能受體激動劑，并具有一定的胃腸道保護(hù)作用，適用于單一治療或與非甾體消炎藥（NSAIDs）聯(lián)合治療急性痙攣性疼痛。通過替扎尼定和非甾體類抗炎藥物的聯(lián)合應(yīng)用，臨床觀察和評估聯(lián)合用藥能否增強(qiáng)療效和增加安全性。方法：急性痙攣性疼痛70例，隨機(jī)分為兩組，一組服用替扎尼定2mg,bid+雙氯芬酸50 mg,bid，一組服用雙氯芬酸50 mg,bid+安慰劑2mg,bid。觀察藥物療效和不良反應(yīng)。結(jié)果：聯(lián)用組的總有效率為70％，胃腸道不良反應(yīng)發(fā)生率為12%,中樞神經(jīng)系統(tǒng)不良反應(yīng)發(fā)生率為18％；單用組的總有效率為56％，胃腸道不良反應(yīng)發(fā)生率為32％，中樞神經(jīng)系統(tǒng)不良反應(yīng)發(fā)生率為10％。結(jié)論：替扎尼定和非甾體類藥物聯(lián)用具有更好的療效以及更高的藥物耐受性。
引用本文： 豐干鈞,劉浩,趙獻(xiàn)峰,梁濤. 替扎尼定與非甾體抗炎藥聯(lián)合治療急性痙攣性疼痛的臨床研究. 華西醫(yī)學(xué), 2008, 23(1): 23-24. doi: 復(fù)制
| 1. | Auchincloss S.The Painful Back:Practical Aspects of Management[J].Oxford:Medicine Publishing Foundation:1983. |
| 2. | Roland M.Back pain-An unresolved problem[J].Talkback,1983,4:4. |
| 3. | Kelsey JK,Cunningham L.Epidemiologic aspects of disability from rheumatic disease.In:Lawrence RC,Shulman LE,eds.Epidemiology of theRheumatic Disease.Vol.42.NewYork:Gower;1984:302-311. |
| 4. | Ehsanullah RSB,Page MC,Tildesley G,Wood JR.Prevention of gastroduoenal damageinduced by no-steroidal anti-inflammatory drugs:Controllede trial of ranitidine[J].BMJ,1988,297:1017-1021. |
| 5. | Bijlsma Jwj.Treatment of endoscopy-negative NSAID-induced upper gastrointestinal sympotoms with cimetidine:An international multicentre collaborative study[J].AZiment Pharmacol Tker,1988,2:75-83. |
| 6. | Davies J,Johnstone SF.Br J Pharmacol 1983,82∶409－21. |
| 7. | Watanabe K,Watanabe H,Maeda-Hagiwara M,Kanaoka R.Influence of a muscle relaxant,tizanidine,on gastric acid secretion and ulcers in the rat[J].Folia Pharmacol(Japan),1983,82:237-245. |
| 8. | McCarthy RJ,Kroni JS,Lubenow TR,et al.Effect of intrathecal tizanidine on antinociception and blood pressure in the rat[J].Pain,1990,40:333-338. |
| 9. | Rameyama T,Nabeshima T,Yamada S.Hypothermic and anti-inflammatory effects of tizanidine[J].Oyo Yakuri(Pharmacometrics),1986,30:867-871. |
| 10. | 龔耀成，梁裕,等.替扎尼定與雙氯芬酸治療急性痙攣性肌痛的比較[J].新藥與臨床，1997,16(5):283-285. |
- 1. Auchincloss S.The Painful Back:Practical Aspects of Management[J].Oxford:Medicine Publishing Foundation:1983.
- 2. Roland M.Back pain-An unresolved problem[J].Talkback,1983,4:4.
- 3. Kelsey JK,Cunningham L.Epidemiologic aspects of disability from rheumatic disease.In:Lawrence RC,Shulman LE,eds.Epidemiology of theRheumatic Disease.Vol.42.NewYork:Gower;1984:302-311.
- 4. Ehsanullah RSB,Page MC,Tildesley G,Wood JR.Prevention of gastroduoenal damageinduced by no-steroidal anti-inflammatory drugs:Controllede trial of ranitidine[J].BMJ,1988,297:1017-1021.
- 5. Bijlsma Jwj.Treatment of endoscopy-negative NSAID-induced upper gastrointestinal sympotoms with cimetidine:An international multicentre collaborative study[J].AZiment Pharmacol Tker,1988,2:75-83.
- 6. Davies J,Johnstone SF.Br J Pharmacol 1983,82∶409－21.
- 7. Watanabe K,Watanabe H,Maeda-Hagiwara M,Kanaoka R.Influence of a muscle relaxant,tizanidine,on gastric acid secretion and ulcers in the rat[J].Folia Pharmacol(Japan),1983,82:237-245.
- 8. McCarthy RJ,Kroni JS,Lubenow TR,et al.Effect of intrathecal tizanidine on antinociception and blood pressure in the rat[J].Pain,1990,40:333-338.
- 9. Rameyama T,Nabeshima T,Yamada S.Hypothermic and anti-inflammatory effects of tizanidine[J].Oyo Yakuri(Pharmacometrics),1986,30:867-871.
- 10. 龔耀成，梁裕,等.替扎尼定與雙氯芬酸治療急性痙攣性肌痛的比較[J].新藥與臨床，1997,16(5):283-285.